National Institute of Pharmaceutical Education and Research (NIPER), Raebareli has signed a Confidential Disclosure Agreement (CDA), and Technology Transfer Agreement with Lofty Laboratories, Hyderabad to foster multidirectional collaboration in research, innovation, and technology commercialisation.

This Memorandum of Understanding (MoU) marks a significant step toward strengthening academia-industry partnerships aimed at advancing pharmaceutical and biotechnology research. During the signing ceremony, both the organisations agreed to adopt an industry-ready technology developed at NIPER-Raebareli for further commercialisation and development. The collaboration will also include joint participation in research and development (R&D) activities in areas of mutual interest.

Speaking during the occasion, Prof. Shubhini A. Saraf, Director, NIPER-Raebareli, stated that the MoU and technology transfer agreement would enable both institutions to complement each other’s research programs in multiple ways, including collaborative participation in the activities of the Institute’s Center of Excellence on Novel Drug Delivery Systems (CoE-NDDS).

Prof. Saraf also highlighted the importance of the technology developed in CoE and expressed hope that several more technologies from the institute would be ready for transfer by the end of the year.

Addressing the gathering, Prof. Nihar Ranjan, Head, CoE-NDDS, explained that commercialisation of the present technology would significantly reduce the cost of gel-staining agents, which are extensively used worldwide in biology-related research, particularly in studies involving genes, cancer, and other nucleic acid-related diseases. He added that indigenous production of such novel gel-staining agents would contribute substantially toward strengthening India’s pharmaceutical and biotechnology sectors.